Company profile: SpringWorks Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted oncology therapies for cancer and rare diseases, focused on innovative treatments for unmet needs. Portfolio includes nirogacestat, an oral gamma secretase inhibitor for desmoid tumors and in evaluation for ovarian granulosa cell tumors and multiple myeloma; mirdametinib, a MEK inhibitor for NF1-associated plexiform neurofibromas; brimarafenib (BGB-3245), a RAF fusion/dimer inhibitor; and SW-682, a TEAD inhibitor.
Products and services
- Brimarafenib (BGB-3245) (RAF Fusion and Dimer Inhibitor): Selective small-molecule inhibitor that targets B-RAF mutations and RAF fusions, evaluated in Phase 1 for advanced or refractory solid tumors
- Mirdametinib (MEK Inhibitor): Phase 2b candidate addressing NF1-associated plexiform neurofibromas, evaluated for low-grade gliomas and in combination with other therapies for MAPK pathway aberrant solid tumors
- Nirogacestat (Gamma Secretase Inhibitor): Oral small-molecule therapy that treats adult patients with progressing desmoid tumors and is evaluated for ovarian granulosa cell tumors and multiple myeloma with BCMA therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SpringWorks Therapeutics
Dren Bio
HQ: United States
Website
- Description: Provider of protein engineering technologies for depleting cells, protein aggregates, and other disease-causing agents. Develops antibody therapeutics including DR-01, a fully human, nonfucosylated ADCC-inducing antibody for hematologic malignancies and autoimmune disorders, and a Targeted Myeloid Engager and Phagocytosis Platform with DR-0201 for B cell malignancies and DR-0202 for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dren Bio company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
Novian Health
HQ: United States
Website
- Description: Provider of proprietary interstitial laser therapy solutions for the focal destruction of breast tumors, including Novilase Breast Therapy, the Interstitial Laser System for breast-conserving procedures, and evidence-generation programs such as the ABLATE Registry and BR-003 clinical trial to support reimbursement and U.S. marketing clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novian Health company profile →
ScandiDos
HQ: Sweden
Website
- Description: Provider of a unique measurement system for radiation therapy in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScandiDos company profile →
Kleo Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics in development, including Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs), to treat cancer, infectious diseases, and other indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kleo Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SpringWorks Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SpringWorks Therapeutics
2.2 - Growth funds investing in similar companies to SpringWorks Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SpringWorks Therapeutics
4.2 - Public trading comparable groups for SpringWorks Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →